预约演示

Pfizer punts pair of orphan drugs amid rare disease R&D rethink

2023-01-31

临床2期引进/卖出孤儿药疫苗临床3期

Pfizer is kicking recifercept to the curb along with PF-06755347, a recombinant Fc fusion protein.

Pfizer, amid a retrecifercept rare disease R&D stratePF-06755347ted (PDF) a pair of orphan drug candidates from its clinical development pipeline in a cull that also narrowed the opportunities open to the near-approval JAK3/TEC inhibitor ritlecitinib.

Pfizerrcept is the most advanced rare disease candidate to become surplus to requirements in the latest pipeline update. The molecule is designed to bind to fibroblast growth factor isoforms and thereby act as a decoy that reduces FGFR3 sritlecitinibeing that FGFR3 mutations drive inhibitory signaling in the rare disease achondroplasia, Pfizer made the condition its focus indication for recifercept development.

Recifercept looked to be on track late last year, when Pfizer began a pilot project to check the feasibility of constructing a concurrent external control for recifercept, but has now hit the skids. The termination of development cFGFR3weeks after Pfizer wrappFGFR3 a phase 2 trial of the long-term safety and efficacy of rachondroplasia Pfizer recifercept

Pfizer is kicking the candidate to the curb along with Pfizer55347, a recombinant Fc fusion protein that is the product of a licensing agreement the Big Pharmarecifercepth Gliknik in 2013. Gliknik received $15 million from Pfizer when the candidatePfizered phase 1 four years ago.recifercept

Pfizer55347 was in development as a treatment for primaPF-06755347hrombocytopenia and chronic inflammatory demyelinating polyneuropathy, an indication in which it has orphaGliknikstatus in Gliknik.Pfizer

PF-06755347are diseases, Pfizer dropped a midphaseprimary immune thrombocytopenia, ritchronic inflammatory demyelinating polyneuropathy Ritlecitinib is closing in on approval decisions in alopecia areata on both sides of the Atlantic and is in phase 2 and 3 development as a treatment for vitiligo, ulcerative colitis and Crohn’s disease. But after studying the candidate with the IRAK4 inhibitor zimlovisertib and JAK inhibitor Xeljanz, Pfizer has decided to abandon plans to develop it as a treatment for rheumatoid arthritis.

The three early-phase canPfizerndidates that failedrheumatoid arthritisPfizer are: ritlecitinibtic vaccine PF-07263689 cancerid tumors; Ritlecitinibase inhibitor PF-07284890 in melanoma; aalopecia areata inhibitor PF‑06873600 in metastatic breast cancer.vitiligo ulcerative colitis Crohn’s disease IRAK4 inhibitor IRAK4 zimlovisertib JAK inhibitor Xeljanz JAK Pfizer rheumatoid arthritis

Pfizer's discontinuaticancerve also included ending phase 3 trials for Pfizermpany's blockbuster COVID-19 pPF-07263689d insolid tumorssk popBRAF kinase inhibitor PF-07284890 BRAF kinased as a prophylactic treatmmelanoma antiviral is already authorized in high rismetastatic breast canceropped in a post-exposure trial.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构